BioSpace News Archive

Business

Biopharma’s 5 Biggest M&A Deals of 2022

See inside for BioSpace’s compilation of the five biggest M&A deals of 2022.

December 14, 2022
·
3 min read
·
George Budwell
Drug Development

Vertex and SpliSense Tackle CF with Novel Inhaled mRNA Approaches

Vertex is kicking off a Phase I trial assessing VX-522, an mRNA therapy designed to treat the underlying cause of cystic fibrosis lung disease, while SpliSense is targeting a specific mutation.

December 14, 2022
·
4 min read
·
Heather McKenzie
Policy

FDA Adcomm Votes Against Cytokinetics’ Heart Failure Drug

The FDA’s Cardiovascular and Renal Drugs Advisory Committee stood against Cytokinetics, Inc., finding that the benefits of its heart failure hopeful didn’t outweigh its risks.

December 14, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Senolytic Therapies Pose Revolutionary Potential to Roll Back Diseases of Aging

While showing early promise, Senolytics is a new field and most of the research is still in academic centers – most notably, the Mayo Clinic.

December 14, 2022
·
6 min read
·
Gail Dutton
Drug Development

Avidity Biosciences Stock Soars On New RNA Data

Shares of Avidity Biosciences are soaring following reported early signs of clinical activity and improvement in patients with myotonic dystrophy type 1 (DM1) treated with its RNA-based therapeutic.

December 14, 2022
·
2 min read
·
Alex Keown
Drug Development

BeiGene’s Brukinsa Outshines Janssen’s Imbruvica in Comparison Trial

In a comparison trial, BeiGene’s Brukinsa bested Janssen’s Imbruvica in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).

December 14, 2022
·
3 min read
·
Tristan Manalac
Employer Resources

Will the Popularity of Remote Work Sustain Through 2023?

The past two years have seen a considerable shift towards remote work, but now that the pandemic is waning, BioSpace has compiled relevant data on remote work to see if it’s here to stay.

December 14, 2022
·
4 min read
·
Franklin Carpenter
Business

First Protein Degrader Tested Outside Oncology Yields Promising Results

Kymera and Sanofi shared positive results for an IRAK4 degrader for hidradenitis suppurativa and atopic dermatitis.

December 14, 2022
·
1 min read
·
Kate Goodwin
Business

Senda Biosciences Appoints MIT Institute Professor Paula Hammond, Ph.D., to Its Board of Directors

Senda Biosciences, Inc. announced the appointment of Paula Hammond, Ph.D., Institute Professor and Head of MIT’s Department of Chemical Engineering, to the Company’s Board of Directors.

December 14, 2022
·
4 min read
Pharm Country

Y-mAbs Announces Pipeline Update - December 14, 2022

Y-mAbs Therapeutics, Inc. announced that a clinical update for naxitamab and the Company’s SADA technology programs will be presented at the Company’s R&D event, which will take place Dec. 14, 2022 at 9 a.m. Eastern Time.

December 14, 2022
·
6 min read